Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8784896 | Advances in Radiation Oncology | 2018 | 16 Pages |
Abstract
In this largest-to-date, modern analysis of PDCRT, the most common cause of discontinuation was discontinuation against medical advice, which underscores the importance of patient education, optimization of RT symptoms, involvement of social work, and integration of other supportive services early in treatment. Survival remains suboptimal after PDCRT for H&N tumors, with a 2-year overall survival rate of 61%. Completing >50âGy appears to confer a relative therapeutic benefit.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Stanislav MD, Vishal MD, Zahra MD, PhD, Brett DDS, MD, FACS, Bethann MD, Krzysztof J. MD, Batya LCSW-R, OSW-C, Ren-Dih PhD, Richard L. MD,